Iovance Biotherapeutics Inc (MIL:1IOVA) Share Price

Company Profile

Business description
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Contact
825 Industrial Road
Suite 100
San CarlosCA94070
USA
T: +1 650 260-7120
E: [email protected]
https://www.iovance.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
975

Recommended

Discounted exit raises investor concerns.

Yingqi Tan, CFA | 21 September 2026

The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.

Jacob Robbins | 21 September 2026

Morningstar analysts’ take on the takeover for this undervalued industrial player.

Esther Holloway | 20 September 2026

Index	Last price	Change	% Change
All Ordinaries	8,919.10	3.60	-0.04%
CAC 40	8,146.19	81.17	1.01%
DAX 40	25,603.14	299.08	1.18%
Dow JONES (US)	51,682.64	95.40	-0.18%
FTSE 100	10,771.23	112.10	1.05%
HKSE	25,042.71	291.93	1.18%
NASDAQ	26,522.54	104.25	0.39%
Nikkei 225	65,018.95	882.70	1.38%
NZX 50 Index	13,821.20	82.06	0.60%
S&P 500	7,650.50	12.74	0.17%
S&P/ASX 200	8,731.90	0.70	0.01%
SSE Composite Index	3,949.91	38.04	0.97%